Post-Embargo News Releases >
Our Embargo Policy Print

Efficacy, Safety of Hydroxychloroquine vs Placebo to Prevent SARS-CoV-2 Infection Among Health Care Workers

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, SEPTEMBER 30, 2020

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2020.6319?guestAccessKey=053387bf-8cfb-4ea9-952c-1dd260fd4aed&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=093020

 

What The Study Did: In this randomized clinical trial, daily hydroxychloroquine didn’t prevent SARS-CoV-2 infection among hospital-based health care workers, although the trial was terminated early.

Authors: Ravi K. Amaravadi, M.D., of the University of Pennsylvania in Philadelphia, is the corresponding author.

 

(doi:10.1001/jamainternmed.2020.6319)

Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.